Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

• Conditions: Virus-HIV; Covid19
• Interventions: Diagnostic Test: Serology test for COVID-19

• Registration Number: NCT04575545
• Lead Sponsor: Hôpital Européen Marseille

Brief Summary

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-09
• Study Start: 2020-10
• Study First Submitted: 2020-10-02
• Study First Submitted QC: 2020-10-02
• Last Update Submitted: 2020-10-02
• Study First Posted: 2020-10-05
• Last Update Posted: 2020-10-05
• Primary Completion: 2021-03
• Study Completion: 2022-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Aged ≥ 18 years
• patients infected by the HIV on treatment
• patients taking PreP (Pre-exposure prophylaxis (PrEP))
• Being affiliated with or benefiting from a social security scheme

Exclusion Criteria

• Subject to a measure for the protection of justice

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients taking PrEP	Serology test for COVID-19	-
HIV positive patients	Serology test for COVID-19	-

Primary Outcome Measures

Name	Time	Method
% of patients with positive serological tests for covid-19	3 months

Secondary Outcome Measures

Name	Time	Method
Presence and quantification of CD4 / CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19	3 months	% of anti-covid positive cells

Trial Locations

Locations (1)

BENNANI; 🇫🇷 Marseille, France